Home Drug Guide Olodaterol Hydrochloride

Drug Guide

Generic Name

Olodaterol Hydrochloride

Brand Names Striverdi Respimat

Classification

Therapeutic: Bronchodilator, Long-Acting Beta-Agonist (LABA)

Pharmacological: Beta-2 adrenergic agonist

FDA Approved Indications

Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD)

Mechanism of Action

Olodaterol is a selective beta-2 adrenergic receptor agonist that stimulates beta-2 receptors in airway smooth muscle, resulting in bronchodilation.

Dosage and Administration

Adult: 2 inhalations (2.5 mcg per inhalation) once daily using the Respimat inhaler.

Pediatric: Not approved for pediatric use.

Geriatric: Dose adjustment not typically necessary but caution advised due to potential comorbidities and medication interactions.

Renal Impairment: No specific dose adjustment recommended.

Hepatic Impairment: No specific dose adjustment recommended.

Pharmacokinetics

Absorption: Rapid absorption after inhalation.

Distribution: Widely distributed throughout the body.

Metabolism: Primarily metabolized by CYP2C8 and CYP2J2 enzymes.

Excretion: Excreted mainly via feces; small amount via urine.

Half Life: Approximately 45 hours.

Contraindications

Known hypersensitivity to olodaterol or any component of the inhaler.

Precautions

Use with caution in patients with cardiovascular disorders, particularly tachyarrhythmias. Not for acute bronchospasm. Monitor for paradoxical bronchospasm.

Adverse Reactions - Common

Nasopharyngitis (Frequent)
Upper respiratory tract infection (Common)
Pharyngolaryngeal pain (Common)

Adverse Reactions - Serious

Paradoxical bronchospasm (Serious but rare)
Cardiac events (e.g., tachycardia, palpitations) (Rare)

Drug-Drug Interactions

Other beta-agonists, beta-blockers (may oppose effects), MAO inhibitors, tricyclic antidepressants

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor respiratory status, cardiac status, and for adverse drug reactions.

Diagnoses:

Ineffective airway clearance related to bronchospasm.
Risk for cardiovascular side effects.

Implementation: Ensure patient education on inhaler use, adherence, and response assessment.

Evaluation: Assess improvement in lung function, symptom relief, and monitor for adverse effects.

Patient/Family Teaching

Use inhaler exactly as prescribed.
Report any worsening symptoms, palpitations, or chest pain.
Do not use more than prescribed.
Keep inhaler accessible but away from children.

Special Considerations

Black Box Warnings:

None currently specified.

Genetic Factors: None specifically identified.

Lab Test Interference: None noted.

Overdose Management

Signs/Symptoms: Severe tachycardia, hypertension, hypokalemia, tremors.

Treatment: Discontinue olodaterol, provide symptomatic treatment, and supportive care. May require administration of beta-blockers in severe cases under medical supervision.

Storage and Handling

Storage: Store at room temperature away from moisture and heat.

Stability: Stable through expiration when stored properly.